BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18757301)

  • 1. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
    Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
    Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
    Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
    Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
    Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
    J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice.
    Li H; Lu H; Griscelli F; Opolon P; Sun LQ; Ragot T; Legrand Y; Belin D; Soria J; Soria C; Perricaudet M; Yeh P
    Gene Ther; 1998 Aug; 5(8):1105-13. PubMed ID: 10326034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells.
    Kanehira M; Xin H; Hoshino K; Maemondo M; Mizuguchi H; Hayakawa T; Matsumoto K; Nakamura T; Nukiwa T; Saijo Y
    Cancer Gene Ther; 2007 Nov; 14(11):894-903. PubMed ID: 17693990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composite implantation of mesenchymal stem cells with endothelial progenitor cells enhances tissue-engineered bone formation.
    Usami K; Mizuno H; Okada K; Narita Y; Aoki M; Kondo T; Mizuno D; Mase J; Nishiguchi H; Kagami H; Ueda M
    J Biomed Mater Res A; 2009 Sep; 90(3):730-41. PubMed ID: 18570318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of multipotent differentiation potentials of murine primary bone marrow stromal cells and mesenchymal stem cell line C3H10T1/2.
    Zhao L; Li G; Chan KM; Wang Y; Tang PF
    Calcif Tissue Int; 2009 Jan; 84(1):56-64. PubMed ID: 19052794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
    Evans CP; Elfman F; Parangi S; Conn M; Cunha G; Shuman MA
    Cancer Res; 1997 Aug; 57(16):3594-9. PubMed ID: 9270033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury.
    Banas A; Teratani T; Yamamoto Y; Tokuhara M; Takeshita F; Osaki M; Kawamata M; Kato T; Okochi H; Ochiya T
    Stem Cells; 2008 Oct; 26(10):2705-12. PubMed ID: 18535155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
    Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
    Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
    Margheri F; D'Alessio S; Serratí S; Pucci M; Annunziato F; Cosmi L; Liotta F; Angeli R; Angelucci A; Gravina GL; Rucci N; Bologna M; Teti A; Monia B; Fibbi G; Del Rosso M
    Gene Ther; 2005 Apr; 12(8):702-14. PubMed ID: 15674398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential.
    Fritz V; Brondello JM; Gordeladze JO; Reseland JE; Bony C; Yssel H; Noël D; Jorgensen C
    J Cell Biochem; 2011 Nov; 112(11):3234-45. PubMed ID: 22009438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of posterolateral spinal fusion using mesenchymal stem cells: differences with or without osteogenic differentiation.
    Nakajima T; Iizuka H; Tsutsumi S; Kayakabe M; Takagishi K
    Spine (Phila Pa 1976); 2007 Oct; 32(22):2432-6. PubMed ID: 18090081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
    Rubin J; Fan X; Rahnert J; Sen B; Hsieh CL; Murphy TC; Nanes MS; Horton LG; Beamer WG; Rosen CJ
    Prostate; 2006 Jun; 66(8):789-800. PubMed ID: 16482567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Wnts in prostate cancer bone metastases.
    Hall CL; Kang S; MacDougald OA; Keller ET
    J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous graft of D1 mouse mesenchymal stem cells leads to the formation of a bone-like structure.
    Juffroy O; Noël D; Delanoye A; Viltart O; Wolowczuk I; Verwaerde C
    Differentiation; 2009 Nov; 78(4):223-31. PubMed ID: 19682787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.